Stock LTRN LANTERN PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-06 EDT 		5-day change 1st Jan Change
6.85 USD +11.38% Intraday chart for Lantern Pharma Inc. +38.95% +60.05%
05-06 Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration MT
05-06 Lantern Pharma Inc. Announces A Strategic AI-Driven Collaboration with Oregon Therapeutics to Optimize the Development of its First-In-Class Protein Disulfide Isomerase Inhibitor Drug Candidate XCE853 in Novel and Targeted Cancer Indications CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration
MT
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
BU
Lantern Pharma Inc. Announces A Strategic AI-Driven Collaboration with Oregon Therapeutics to Optimize the Development of its First-In-Class Protein Disulfide Isomerase Inhibitor Drug Candidate XCE853 in Novel and Targeted Cancer Indications
CI
Lantern Pharma to Report First Quarter 2024 Operating and Financial Results on May 9th, 2024 at 4:30 p.m. ET
AQ
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
BU
Lantern Pharma Launches Webinar Wednesdays Featuring World-Class Physician Scientists and Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
AQ
Transcript : Lantern Pharma Inc. - Special Call
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
BU
Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
AQ
Lantern Gets Regulatory Approval in Japan, Taiwan for Non-Small Cell Lung Cancer Trial Expansion
MT
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
BU
Lantern Pharma Inc. Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smakers into Japan and Taiwan
CI
Lantern Pharma : Corporate Overview
PU
Transcript : Lantern Pharma Inc., Q4 2023 Earnings Call, Mar 18, 2024
Lantern Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
BU
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
BU
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, Lp-284
CI
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
BU
Lantern to Participate in H.C Wainwright and Co.'s 1st Annual Artificial Intelligence Based Drug Discovery and Development Virtual Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LTRN Stock
  4. News Lantern Pharma Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW